Table 1.
Demographic and clinical characteristics of systemic lupus erythematosus patients
| Characteristic | Value |
|---|---|
| Age, years, mean ± SD |
40.4 ± 14.5 |
| Gender, female/male, n (%) |
56 (91.8%)/5 (8.2%) |
| Disease duration years, mean ± SD |
5.4 ± 4.9 |
| Anti-ds DNA Ab-positive, n (%) |
23 (62.3%) |
| C3, mean ± SD |
90.5 ± 26.6 |
| C4, mean ± SD |
14.3 ± 7.1 |
| CH50, mean ± SD |
110.6 ± 31.9 |
| SLEDAI, mean ± SD |
4.2 ± 4.2 |
| ECLAM, mean ± SD |
1.9 ± 1.9 |
| SIS, mean ± SD |
3.6 ± 2.9 |
| Current prednisone dose, mg/day, mean ± SD |
10.4 ± 15.3 |
| Concurrent immunosuppressive therapy, n (%) |
|
| Hydroxychloroquine |
22 (36.1%) |
| Mycophenolate mofetil |
9 (14.8%) |
| Cyclophosphamide |
6 (9.8%) |
| Azathioprine |
8 (13.1%) |
| Methotrexate |
5 (8.2%) |
| Organ involvement, n (%) |
|
| Skin/active |
37 (60.7.1%)/8 (13.1%) |
| Hematologic/active |
23 (37.7%)/10 (16.4%) |
| Arthritis/active |
22 (36.1%)/3 (4.9%) |
| Serositis/active |
8 (13.1%)/2 (3.3%) |
| Renal/active | 25 (40.9%)/13 (21.3%) |
SLEDAI, systemic lupus erythematosus disease activity index; ECLAM, European Consensus Lupus Activity Measurement; SIS, systemic lupus erythematosus index score.